Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Sunday, November 1, 2026

Back to today

From X

@convequity 1 click

Convequity on X

Strange short report on Cerebras $CBRS. Wafer-scale power and thermal constraints are longstanding engineering challenges. They can force compromises on clock speed versus a smaller die. That doesn't mean unacceptable overall performance. CS-4 is getting more out of WSE-3T, with the same core count and SRAM capacity as WSE-3, through higher clocks and improved I/O. Cerebras attributes the higher clocks to better power delivery. My read is that earlier systems left performance on the table to stay within power and thermal limits. Directionally, Cerebras looks to be working through those constraints better than I expected. Higher clocks alone don't answer the lifespan allegation. I’d still want to know how representative those failures are of current systems. I also give weight to Oracle, OpenAI and AWS choosing to work with Cerebras.
@BrokenMoats

Broken Moats on X

$now bill is always selling and some people on here seem confused why the stock is down when they look at the numbers he directs you to. Wash away all of his puffery and the underlying business deteriorated - gross profit came in at 10%+ yoy (which I believe is the lowest ever) for the quarter. You can call anything revenue but it's ultimately about the gross profit dollars you bring in + the efficiency of your expense management, which if you look saw increases across the board with profit materially weakening. You can argue intangibles on the COGS but then you need to adjust the light crpo further to exclude all the inorganic revenue helping out in there (which the co did not strip out).....the street is not fooled, these were not great numbers. And swapping revenue to juice AI in a press release while total sales stays on trend is not going to work anymore, as one analyst put it best to Bill "I wanted to just zoom out a little bit and just talk about the momentum you're seeing on the AI ACV side. Gina as you noted, you've raised the guidance twice now to $1.7 billion in revenue. At the same time, if we look at just the broad story of cRPO, we could call it stable, maybe on an organic basis, modestly decelerating, but sort of generally stable. So my high-level question, Bill, is just when do you think the AI momentum will start to translate to overall top line acceleration, cRPO acceleration?" There are very different expectations when a stock doubles in a quarter in-between reporting results.....
@orrdavid

David Orr on X

Another thing: This post is *not* meant to call a short term top. I sometimes want to. Maybe even I have hinted that's what I think. But that's wrong. The best way to think is, "I don't know when the top will be, maybe $SOXX really does take another 100% leg up first, who knows, why not." But that next big move up or down seems like a pure guess to me. So at least for making a binary bet - a bet on $SOXX beta - it's a pure casino. There probably is some brilliant way to structure this trade, though. You're long compute and you're short the things that more intelligence kills - like really kills, not that benefits from AI letting them cut 90% of their staff. For my part, there are just way too many eyes on the trade for me to be all that interested, though. Because if too many smart people figure out how to solve that fundamentally guess what ... the long/short could easily blow up in a month, just before the collapse, since the market won't often give such large crowds a free lunch pair trade. I say screw all of that, better to just focus on real investments, in the real world, that likely benefit from AI or at least don't get hurt. That is not a gamble today, and lots of those stocks are just straight up cheap. The only downside is that the AI trade will probably keep the stocks trading weak ... but this side is NOT hard to do broad, uncrowded pair trades on, so who cares.
@ParadisLabs 1 click

Paradis on X

Initial notes on $MRVL's rumoured $LITE acquisition: 1. Why?! - $LITE's CEO has said they're sold out into 2029. So do management think the InP laser shortage is shorter than what their orders suggest? Need more clarity on why Lumentum would green light this. - With lasers sold out into 2029, I think owning the fab might be the only way $MRVL can guarantee supply for FY28 growth. So maybe Marvell and Lumentum have different reads on the InP laser shortage? 2. This has to be mostly stock. - $MRVL has ~$3.9B cash vs. $5.0B debt. Combined run-rate EBITDA is circa $7-7.5B (my numbers), so I think staying investment grade caps new debt at around $15-20B. - At a ~30% premium that leaves $85-90B+ paid in stock, with $LITE holders owning ~30% of the combined company. - I feel that’s a lot of Marvell to hand over. 3. I think the strategy is much better than the reaction. - $MRVL are essentially buying the part of the optical link that survives the move to CPO which is a pretty smart hedge on their own DSP franchise. - Marvell announced Inphi around 6 years ago (~$10B in cash + stock), and that deal built the core of MRVL's optics business. - This is basically the same move just one layer down, from DSP to laser, stacked on Celestial AI. - Probably a good signal that Marvell are running the same optics playbook again? 4. Dilution. - $MRVL trades on about 52x run rate EPS. - $LITE is about 60x on its FQ1 guide at tonight's AH price and about 70x with a 30% premium. - That's ~15% dilutive to Marvell's run-rate EPS (my rough napkin math number) assuming a 30% premium, ~$17.5B of new debt at ~5%, and the rest in stock at $228. (Again, very rough numbers). - It only turns accretive if Lumentum keeps outgrowing Marvell at today's guided rates (+24% q/q vs +15%) for another five or six quarters. - I think that's achievable while the laser shortage lasts, but I feel the whole deal ends up being a bet on how long that is. 5. Fewer lasers on the open market. - If LITE's output gets prioritised for $NVDA and Marvell's own modules, everyone else buying LITE EMLs and CW lasers gets tighter allocation. - I think that's bullish for laser pricing at $COHR and for other laser sources like $SIVE (lol). - Feels like the module makers that depend on LITE lasers are the quiet losers. 6. Channel conflict. - Marvell is the leading DSP supplier to 800G/1.6T module makers, and LITE already sells its own modules through Cloud Light. - I think Innolight and Eoptolink start shifting DSP share to $AVGO and $CRDO? - I feel hyperscalers will push harder to second-source lasers from $COHR.

Investor Letters

All letters

When the liquidity does not add up

Arbor Realty Trust’s dividend suspension is presented as creating $60 million of liquidity, raising questions about its ability to meet…

ABR $2.2B
John Hempton's Newsletter 3 clicks

Verra veerer

Verra Mobility’s Avis termination threatens 2027 earnings, while Government Solutions profit rose 25% and implied fourth-quarter guidance…

VRRM $505M
The Oak Bloke 2 clicks

FTAI 3Q26: Aero margins in focus

FTAI’s Aerospace Products margin rebounded to 31% as CFM56 module output rose, while Power deposits and contracted deliveries fund its 2027…

FTAI $16B
Stock Thoughts 4 clicks

CVX Earnings Review

Chevron’s Q3 revenue rose 35% to $65.2 billion and EBITDA 75% to $20.2 billion, while production trailed guidance and refining margins…

CVX $465B
Cestrian Capital Research 3 clicks
T · short

At&t INC

AT&T’s stalled deleveraging and share repurchase case has prompted a bearish turn on the telecom stock.

T $144B
Value Investors Club

SNY Earnings Review

Sanofi raised FY26 guidance after Q3 sales grew 14.3% at constant currency, led by 34.8% Dupixent growth; vaccines declined 6.6%.

SNY $108B
Cestrian Capital Research 1 click

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 67 of 268

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

190 firms

Sectors

Ordered by how often our editor reaches for them.